Men and women at least 18 years of age with moderate-to-severe ulcerative colitis for a least 3 months prior to enrollment are eligible to participate
This is a global, observational, prospective, long-term, exposure registry of adult patients with moderate-to-severe ulcerative colitis who are treated with Simponi or thiopurines in a routine clinical setting. Two cohorts, a Simponi -exposed cohort and a comparator cohort.
Eligibility:
Patients currently receiving Simponi, patients who are still receiving Simponi after participation in an ulcerative colitis study supported by the sponsor, or patients scheduled to receive Simponi within 30 days after enrollment.